|Referral date||June 2015|
Scoped as part of Batch 41
|24 February 2016||Expected publication|
|18 February 2016||Guidance published|
|22 January 2016 - 05 February 2016||Final appraisal determination|
Following the CHMP positive opinion, the company met with the NICE team and proposed that the three scopes for nivolumab monotherapy (ID845, ID846 and ID847) could be combined into one Single Technology Appraisal (STA), with a second STA for nivolumab in combination with ipilimumab (ID848) to follow in line with the proposed license extension.
At the Decision Point 4 meeting, following the draft scope consultation and scoping workshop this approach was agreed.
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance